Analyst Ratings for [XNCR] Xencor, Inc.

12/12/24	Initiated	Overweight	X
XNCR Xencor Wells Fargo
$37
12/2/24	Upgrades	Neutral Overweight	X
XNCR Xencor Piper Sandler
$20 $30
4/16/24	Reiterated	Buy	X
XNCR Xencor BTIG Research
$56 $38
2/28/24	Downgrades	Overweight Neutral	X
XNCR Xencor Piper Sandler
$37 $24
5/19/23	Initiated	Buy	X
XNCR Xencor BofA Securities
$42
12/6/22	Initiated	Outperform	X
XNCR Xencor Cowen
10/13/22	Upgrades	Outperform Strong Buy	X
XNCR Xencor Raymond James
$58
9/21/22	Initiated	Overweight	X
XNCR Xencor JP Morgan
$37
7/6/22	Resumed	Buy	X
XNCR Xencor Canaccord Genuity
$50
2/11/22	Initiated	Outperform	X
XNCR Xencor BMO Capital Markets
$54
1/21/22	Initiated	Outperform	X
XNCR Xencor SMBC Nikko
$60
12/15/21	Initiated	Buy	X
XNCR Xencor H.C. Wainwright
$61
10/15/21	Resumed	Buy	X
XNCR Xencor BTIG Research
$56
2/24/21	Upgrades	Mkt Perform Outperform	X
XNCR Xencor Raymond James
$58
8/7/19	Downgrades	Buy Neutral	X
XNCR Xencor Guggenheim
8/7/19	Downgrades	Outperform Mkt Perform	X
XNCR Xencor Raymond James
6/13/19	Initiated	Buy	X
XNCR Xencor Mizuho
4/12/19	Initiated	Buy	X
XNCR Xencor Guggenheim
3/27/19	Initiated	Buy	X
XNCR Xencor Berenberg
$45
3/15/19	Initiated	Outperform	X
XNCR Xencor Raymond James
9/10/18	Resumed	Buy	X
XNCR Xencor BTIG Research
$56
3/28/18	Resumed	Outperform	X
XNCR Xencor Leerink Partners
$36

XNCR Xencor, Inc.

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Xencor, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases. It is also developing a pipeline of bispecific antibody candidates using its heterodimer Fc bispecific technology: XmAb14045, which is in a Phase I trial for the treatment of acute myeloid leukemia (AML); XmAb13676, which is in a Phase I trial for the treatment of B-cell malignancies; XmAb18087, which is in preclinical development for the treatment of neuroendocrine tumors, and XmAb20717, which is in preclinical development for the treatment of various cancers and is its dual checkpoint inhibitor.